You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThiopental
Accession NumberDB00599  (APRD00660)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
Structure
Thumb
Synonyms
(+-)-Thiopental
2-Thio-5-ethyl-5-sec-pentylbarbituric acid
5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione
Bitaryl
Omexolon
Penthiobarbital
Pentothiobarbital
Sodium Pentothal
Thiomebumalum
Thiopental
Thiopentobarbital
Thiopentobarbitone
Thiopentobarbituric acid
Thiopentone
Tiopentale
Trapanal
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pentothal Inj 25mg/mlpowder for solution25 mgintravenousHospira Healthcare Corporation1988-12-31Not applicableCanada
Pentothal Inj 500mg/syrpowder for solution500 mgintravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Pentothal Ready To Mix Syringe 250mgpowder for solution250 mgintravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Pentothal Sodium Inj 1gm Sterilepowder for solution1 gintravenousHospira Healthcare Corporation1951-12-31Not applicableCanada
Pentothal Sodium Pws 5gmpowder for solution5 gintravenousHospira Healthcare Corporation1975-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnesthoIncepta
BensulfFada
Bitol SodiumBrookes
EkipentalTüm Ekip
FarmotalMarvecs Pharma Services
Intraval SodiumAbbott
Pental SodyumI.E. Ulagay
PentazolSwiss Parenterals
PenthalOboi
Penthotal SodiumAbbott
PentotanChoong Wae
PentotexRotexmedica
PentothalHospira
RavonalRavonal
ThiopenACI
TiopentalRichmond
TrapanalNycomed
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thiopental sodium
ThumbNot applicableDBSALT001409
Categories
UNIIJI8Z5M7NA3
CAS number76-75-5
WeightAverage: 242.338
Monoisotopic: 242.10889852
Chemical FormulaC11H18N2O2S
InChI KeyInChIKey=IUJDSEJGGMCXSG-UHFFFAOYSA-N
InChI
InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-ethyl-5-(pentan-2-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
SMILES
CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thiobarbituric acid derivatives. These are organic compounds containing a 2-thioxodihydropyrimidine-4,6(1H,5H)-dione skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentThiobarbituric acid derivatives
Alternative Parents
Substituents
  • Thiobarbiturate
  • 1,3-diazinane
  • Thiourea
  • Thiocarbonic acid derivative
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.
PharmacodynamicsThiopental, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Thiopental is an ultrashort-acting depressant of the central nervous system which induces hypnosis and anesthesia, but not analgesia. It produces hypnosis within 30 to 40 seconds of intravenous injection. Recovery after a small dose is rapid, with some somnolence and retrograde amnesia. Repeated intravenous doses lead to prolonged anesthesia because fatty tissues act as a reservoir; they accumulate Pentothal in concentrations 6 to 12 times greater than the plasma concentration, and then release the drug slowly to cause prolonged anesthesia
Mechanism of actionThiopental binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionRapidly absorbed.
Volume of distributionNot Available
Protein bindingApproximately 80% of the drug in the blood is bound to plasma protein.
Metabolism

Primarily hepatic. Biotransformation products of thiopental are pharmacologically inactive and mostly excreted in the urine.

Route of eliminationNot Available
Half life3-8 hours
ClearanceNot Available
ToxicityOverdosage may occur from too rapid or repeated injections. Too rapid injection may be followed by an alarming fall in blood pressure even to shock levels. Apnea, occasional laryngospasm, coughing and other respiratory difficulties with excessive or too rapid injections may occur. Lethal blood levels may be as low as 1 mg/100 mL for short-acting barbiturates; less if other depressant drugs or alcohol are also present.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5106
Blood Brain Barrier+0.9505
Caco-2 permeable-0.5463
P-glycoprotein substrateNon-substrate0.5623
P-glycoprotein inhibitor INon-inhibitor0.5373
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.9031
CYP450 2C9 substrateNon-substrate0.8052
CYP450 2D6 substrateNon-substrate0.858
CYP450 3A4 substrateNon-substrate0.6688
CYP450 1A2 substrateNon-inhibitor0.8297
CYP450 2C9 inhibitorNon-inhibitor0.5588
CYP450 2D6 inhibitorNon-inhibitor0.914
CYP450 2C19 inhibitorNon-inhibitor0.5927
CYP450 3A4 inhibitorNon-inhibitor0.8813
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8482
Ames testNon AMES toxic0.6907
CarcinogenicityNon-carcinogens0.8992
BiodegradationNot ready biodegradable0.9917
Rat acute toxicity2.7671 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9827
hERG inhibition (predictor II)Non-inhibitor0.6314
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories hosp products div
Packagers
Dosage forms
FormRouteStrength
Powder for solutionintravenous25 mg
Powder for solutionintravenous500 mg
Powder for solutionintravenous250 mg
Powder for solutionintravenous1 g
Powder for solutionintravenous5 g
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.85HANSCH,C ET AL. (1995)
logS-3.36ADME Research, USCD
pKa7.55SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0398 mg/mLALOGPS
logP3.05ALOGPS
logP2.78ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity65.99 m3·mol-1ChemAxon
Polarizability25.7 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.6 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0596-9600000000-1b2c7562818b87a3dce1View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Morgan DJ, Blackman GL, Paull JD, Wolf LJ: Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. Anesthesiology. 1981 Jun;54(6):474-80. [PubMed:7235275 ]
  2. Perez-Barcena J, Barcelo B, Homar J, Abadal JM, Molina FJ, de la Pena A, Sahuquillo J, Ibanez J: [Comparison of the effectiveness of pentobarbital and thiopental in patients with refractory intracranial hypertension. Preliminary report of 20 patients]. Neurocirugia (Astur). 2005 Feb;16(1):5-12; discussion 12-3. [PubMed:15756405 ]
  3. WINTERS WD, SPECTOR E, WALLACH DP, SHIDEMAN FE: Metabolism of thiopental-S35 and thiopental-2-C14 by a rat liver mince and identification of pentobarbital as a major metabolite. J Pharmacol Exp Ther. 1955 Jul;114(3):343-57. [PubMed:13243246 ]
  4. Bory C, Chantin C, Boulieu R, Cotte J, Berthier JC, Fraisse D, Bobenrieth MJ: [Use of thiopental in man. Determination of this drug and its metabolites in plasma and urine by liquid phase chromatography and mass spectrometry]. C R Acad Sci III. 1986;303(1):7-12. [PubMed:3093002 ]
External Links
ATC CodesN05CA19N01AF03
AHFS Codes
  • 28:04.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with 7-Nitroindazole.
AcebutololThiopental may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Thiopental.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Thiopental.
AceprometazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Thiopental.
AcetazolamideThiopental may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Thiopental is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Thiopental is combined with Agomelatine.
AldesleukinThiopental may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Thiopental.
AliskirenThiopental may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thiopental is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiopental.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Thiopental.
AmilorideThiopental may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Thiopental.
AminophyllineThe therapeutic efficacy of Thiopental can be decreased when used in combination with Aminophylline.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Thiopental.
AmisulprideThe risk or severity of adverse effects can be increased when Thiopental is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Thiopental is combined with Amitriptyline.
AmlodipineThiopental may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Thiopental is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Thiopental is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Thiopental.
Amyl NitriteThiopental may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineThiopental may increase the hypotensive activities of Apraclonidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with Aripiprazole.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Thiopental.
ArticaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Thiopental is combined with Asenapine.
AtenololThiopental may increase the hypotensive activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Azaperone.
AzelastineThiopental may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Thiopental.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Thiopental.
Azilsartan medoxomilThiopental may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Thiopental.
BaclofenThe risk or severity of adverse effects can be increased when Thiopental is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Thiopental.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Thiopental.
BenazeprilThiopental may increase the hypotensive activities of Benazepril.
BendroflumethiazideThiopental may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Thiopental.
BenzocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiopental is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Thiopental.
BetaxololThiopental may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Thiopental.
BisoprololThiopental may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Thiopental.
BretyliumThiopental may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
BrimonidineThiopental may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Thiopental.
BumetanideThiopental may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiopental.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Thiopental.
BuprenorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiopental.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiopental.
ButacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Thiopental is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Thiopental is combined with Butorphanol.
CanagliflozinThiopental may increase the hypotensive activities of Canagliflozin.
CandesartanThiopental may increase the hypotensive activities of Candesartan.
CaptoprilThiopental may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiopental.
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Thiopental is combined with Carisoprodol.
CarteololThiopental may increase the hypotensive activities of Carteolol.
CarvedilolThiopental may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Thiopental.
CetirizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Thiopental is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Thiopental can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiopental.
ChlormezanoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Chloroprocaine.
ChlorothiazideThiopental may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiopental.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorprothixene.
ChlorthalidoneThiopental may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorzoxazone.
CilazaprilThiopental may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Thiopental.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiopental.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Thiopental.
CitalopramThe risk or severity of adverse effects can be increased when Thiopental is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Thiopental is combined with Clemastine.
ClevidipineThiopental may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Thiopental is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Thiopental is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Thiopental is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Clonazepam.
ClonidineThiopental may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Thiopental.
ClorazepateThe risk or severity of adverse effects can be increased when Thiopental is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiopental.
CocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiopental.
CyclizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Thiopental.
CyproheptadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Thiopental is combined with Dantrolene.
DapagliflozinThiopental may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiopental.
DapoxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Thiopental.
deramciclaneThe risk or severity of adverse effects can be increased when Thiopental is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Thiopental is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dexbrompheniramine.
DexmedetomidineThiopental may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiopental.
DextromoramideThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Diazepam.
DiazoxideThiopental may increase the hypotensive activities of Diazoxide.
DiclofenamideThiopental may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Thiopental.
DifenoxinThe risk or severity of adverse effects can be increased when Thiopental is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydromorphine.
DiltiazemThiopental may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiopental is combined with Dimenhydrinate.
DinutuximabThiopental may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Thiopental is combined with Diphenoxylate.
DipyridamoleThiopental may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Thiopental is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Thiopental.
DotarizineThe metabolism of Dotarizine can be increased when combined with Thiopental.
DoxazosinThiopental may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Thiopental is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Thiopental.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
DoxylamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Thiopental is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Thiopental.
DrotebanolThe risk or severity of adverse effects can be increased when Thiopental is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Thiopental.
EcgonineThe risk or severity of adverse effects can be increased when Thiopental is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thiopental is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Thiopental is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Thiopental.
EmpagliflozinThiopental may increase the hypotensive activities of Empagliflozin.
EnalaprilThiopental may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiopental.
EntacaponeThe risk or severity of adverse effects can be increased when Thiopental is combined with Entacapone.
EperisoneThe metabolism of Eperisone can be increased when combined with Thiopental.
EplerenoneThiopental may increase the hypotensive activities of Eplerenone.
EprosartanThiopental may increase the hypotensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Thiopental.
EsmololThiopental may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiopental.
Etacrynic acidThiopental may increase the hypotensive activities of Etacrynic acid.
EthanolThiopental may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Thiopental.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental.
EthosuximideThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiopental.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Thiopental is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.
EtoperidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Thiopental is combined with Ezogabine.
FelbamateThe serum concentration of Thiopental can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Thiopental is combined with Felbamate.
FelodipineThiopental may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Thiopental.
FenfluramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Thiopental is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Thiopental is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Thiopental.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Thiopental.
FlunitrazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Thiopental is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiopental.
FlurazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluvoxamine.
FosinoprilThiopental may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Thiopental is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Thiopental is combined with Fospropofol.
FurosemideThiopental may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Thiopental.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiopental.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thiopental is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Thiopental is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Thiopental is combined with Glutethimide.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Thiopental.
GuanfacineThiopental may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Thiopental.
HalazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.
HalothaneThe risk or severity of adverse effects can be increased when Thiopental is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Thiopental is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Hexobarbital.
HydralazineThiopental may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideThiopental may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Hydrocodone.
HydroflumethiazideThiopental may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopental.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
HydroxyzineThe risk or severity of adverse effects can be increased when Thiopental is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Thiopental is combined with Indalpine.
IndapamideThiopental may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Thiopental.
IrbesartanThiopental may increase the hypotensive activities of Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Thiopental is combined with Isoflurane.
Isosorbide DinitrateThiopental may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateThiopental may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineThiopental may increase the hypotensive activities of Isoxsuprine.
IsradipineThiopental may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiopental.
KetazolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketobemidone.
LabetalolThiopental may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Thiopental.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Thiopental.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Thiopental.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Thiopental.
LevetiracetamThe risk or severity of adverse effects can be increased when Thiopental is combined with Levetiracetam.
LevobunololThiopental may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Thiopental is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Thiopental is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Thiopental is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Thiopental.
LisinoprilThiopental may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiopental.
LosartanThiopental may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiopental.
Lu AA21004The risk or severity of adverse effects can be increased when Thiopental is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Thiopental.
ManidipineThe metabolism of Manidipine can be increased when combined with Thiopental.
MannitolThiopental may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Thiopental is combined with Maprotiline.
MecamylamineThiopental may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Thiopental is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Thiopental can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Thiopental is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiopental.
MetaxaloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiopental.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thiopental is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Thiopental is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Methaqualone.
MethazolamideThiopental may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Thiopental is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiopental.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Thiopental.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Thiopental is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Thiopental is combined with Methsuximide.
MethyclothiazideThiopental may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaThiopental may increase the hypotensive activities of Methyldopa.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Thiopental.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methylphenobarbital.
MetipranololThiopental may increase the hypotensive activities of Metipranolol.
MetolazoneThiopental may increase the orthostatic hypotensive activities of Metolazone.
MetoprololThiopental may increase the hypotensive activities of Metoprolol.
MetyrosineThiopental may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
MibefradilThe metabolism of Mibefradil can be increased when combined with Thiopental.
MidazolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Thiopental is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
MinoxidilThiopental may increase the hypotensive activities of Minoxidil.
MirtazapineThiopental may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiopental.
MoexiprilThiopental may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Molindone.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Thiopental.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiopental.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiopental.
NabiloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Nabilone.
NadololThiopental may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Thiopental is combined with Nalbuphine.
NebivololThiopental may increase the hypotensive activities of Nebivolol.
NesiritideThiopental may increase the hypotensive activities of Nesiritide.
NicardipineThiopental may increase the hypotensive activities of Nicardipine.
NifedipineThiopental may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Thiopental.
NiludipineThe metabolism of Niludipine can be increased when combined with Thiopental.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Thiopental.
NimesulideThe metabolism of Nimesulide can be increased when combined with Thiopental.
NimodipineThiopental may increase the hypotensive activities of Nimodipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Thiopental.
NisoldipineThiopental may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Thiopental.
NitroglycerinThiopental may increase the hypotensive activities of Nitroglycerin.
NitroprussideThiopental may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Thiopental is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Thiopental is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Thiopental is combined with Olanzapine.
OlmesartanThiopental may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Thiopental is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Thiopental is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Thiopental is combined with Opium.
OrlistatThe serum concentration of Thiopental can be decreased when it is combined with Orlistat.
OrphenadrineThiopental may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thiopental.
OsanetantThe risk or severity of adverse effects can be increased when Thiopental is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxazepam.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Thiopental.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiopental.
OxybuprocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopental.
OxymorphoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Paliperidone.
PapaverineThiopental may increase the hypotensive activities of Papaverine.
ParaldehydeThiopental may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Thiopental.
ParoxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine.
PenbutololThiopental may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Thiopental is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiopental.
PerampanelThe risk or severity of adverse effects can be increased when Thiopental is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Thiopental.
PerindoprilThiopental may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Thiopental is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopental.
PethidineThiopental may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiopental.
PhenindioneThe metabolism of Phenindione can be increased when combined with Thiopental.
PhenobarbitalThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Thiopental.
PhenytoinThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Thiopental is combined with Pimozide.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Thiopental.
PindololThiopental may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Thiopental is combined with Pizotifen.
PolythiazideThiopental may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Thiopental is combined with Pomalidomide.
PractololThe serum concentration of Practolol can be decreased when it is combined with Thiopental.
PramipexoleThiopental may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Prazepam.
PrazosinThiopental may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Thiopental.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiopental.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Thiopental.
PrilocaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Thiopental.
ProcaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Thiopental.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiopental.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Thiopental.
ProparacaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Thiopental is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Propoxycaine.
PropranololThiopental may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Thiopental is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Thiopental is combined with PSD502.
PyridoxineThe metabolism of Thiopental can be increased when combined with Pyridoxine.
QuazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Quazepam.
QuetiapineThiopental may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiopental.
QuinaprilThiopental may increase the hypotensive activities of Quinapril.
QuinethazoneThiopental may increase the orthostatic hypotensive activities of Quinethazone.
RamelteonThe risk or severity of adverse effects can be increased when Thiopental is combined with Ramelteon.
RamiprilThiopental may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental.
ReserpineThiopental may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiopental.
RiociguatThiopental may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Thiopental.
RisperidoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Romifidine.
RopiniroleThiopental may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiopental.
RotigotineThiopental may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiopental.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thiopental is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiopental.
SertindoleThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Thiopental is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Thiopental is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Thiopental.
SotalolThiopental may increase the hypotensive activities of Sotalol.
SpironolactoneThiopental may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Thiopental is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Thiopental is combined with Sufentanil.
SulfisoxazoleThe therapeutic efficacy of Thiopental can be increased when used in combination with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiopental.
SuvorexantThe risk or severity of adverse effects can be increased when Thiopental is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Thiopental is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Thiopental is combined with Tasimelteon.
TelmisartanThiopental may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiopental.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Thiopental.
TerazosinThiopental may increase the hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrodotoxin.
ThalidomideThiopental may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thiopental.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Thiopental.
ThiamylalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiamylal.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiopental.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Thiopental.
TiletamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiletamine.
TimololThiopental may increase the hypotensive activities of Timolol.
TizanidineThiopental may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiopental.
TolcaponeThe risk or severity of adverse effects can be increased when Thiopental is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Thiopental.
TopiramateThe risk or severity of adverse effects can be increased when Thiopental is combined with Topiramate.
TorasemideThiopental may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiopental.
TrandolaprilThiopental may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Thiopental.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiopental is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.
TriamtereneThiopental may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Thiopental is combined with Triazolam.
TrichlormethiazideThiopental may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopental.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiopental.
TrimipramineThe risk or severity of adverse effects can be increased when Thiopental is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Thiopental.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Thiopental.
ValsartanThiopental may increase the hypotensive activities of Valsartan.
VerapamilThiopental may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Thiopental is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Thiopental is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Thiopental.
VortioxetineThe risk or severity of adverse effects can be increased when Thiopental is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Thiopental.
XylazineThe risk or severity of adverse effects can be increased when Thiopental is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Thiopental.
ZaleplonThe risk or severity of adverse effects can be increased when Thiopental is combined with Zaleplon.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Thiopental.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Thiopental.
ZimelidineThe risk or severity of adverse effects can be increased when Thiopental is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiopental.
ZolazepamThe risk or severity of adverse effects can be increased when Thiopental is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thiopental.
ZonisamideThe risk or severity of adverse effects can be increased when Thiopental is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Thiopental is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Thiopental is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Thiopental is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Grasshoff C, Netzhammer N, Schweizer J, Antkowiak B, Hentschke H: Depression of spinal network activity by thiopental: shift from phasic to tonic GABA(A) receptor-mediated inhibition. Neuropharmacology. 2008 Oct;55(5):793-802. doi: 10.1016/j.neuropharm.2008.06.026. Epub 2008 Jun 21. [PubMed:18619475 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Fatty acid amide hydrolase activity
Specific Function:
Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.
Gene Name:
FAAH
Uniprot ID:
O00519
Molecular Weight:
63065.28 Da
References
  1. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WB, Hillard CJ: The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13. [PubMed:12839875 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23